ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO1653

A Multicenter, Prospective, Open-Labeled Study of Acthar Gel Alone or with Tacrolimus to Reduce Urinary Proteinuria in Patients with Idiopathic DNA-JB9-Positive Fibrillary Glomerulopathy

Session Information

Category: Glomerular Diseases

  • 1203 Glomerular Diseases: Clinical, Outcomes, and Trials


  • Tumlin, James A., Emory University, Atlanta, Georgia, United States
  • Lafayette, Richard A., Stanford University, Stanford, California, United States
  • Bomback, Andrew S., Columbia University, New York, New York, United States
  • Podoll, Amber S., University of Colorado - Anschutz Medical Campus, Aurora, Colorado, United States

Group or Team Name

  • FACT Trial Group

Fibrillary Glomerulopathy (FGN) is a rare primary glomerular disease characterized by glomerular accumulation of nonbranching, randomly arranged 10-30 nm in diameter fibrils. The resulting podocyte dysfunction and progressive proteinuria leads to ESRD rates of 50% within 4 years. Herein we present data on 15 patients treated with ACTH or ACTH + Tacrolimus completing 12 months of therapy.


Study Design: Randomized prospective open labeled study of 12 months of SQ ACTH alone or with Tacrolimus in 15 patients with biopsy proven, DNA-B9 + Fibrillary glomerulopathy.
Study Drug Dosing: ACTH 80 units SQ 2X/week, Tacrolimus-1.0 mg PO BID.
Primary Endpoint: Change in UP/Cr ratio (mg/gm) in patients after 12 months of ACTHar gel alone or in combination with Tracrolimus
Definitions: Responders-Complete-Partial-Clinical response defined at < 300 mg/gm or > 50% reduction or > 30% reduction in UP/Cr from baseline at 12 months.


Of the 15 patients completing 12 months of treatment, 14.3% acheived complete remission (UP/Cr ratio < 300 mg/gm); 26.0% acheived a > 75% reduction from baseline, while 60.7% acheived a > 50% reduction in UP/Cr at 12 months. A total of 86.6% acheived a minimum 30% reduction in UP/Cr. The addition of Tacrolimus to ACTH tended to further lower UP/Cr at 12 months (1654.7+317 vs.4449.5+1665 ) respectively, but did not reach statistical significance


In summary, depo-repository ACTH induced a complete or partial remission in 75% of patients with DNA-JB9 + Fibrillary GN. The addition of Tacrolimus in this population tended to improve complete-partial response rates.

Responder Group

Non-Responder Group


  • Commercial Support